Inhibition of mTOR using rapamycin and its analogs has shown reduction in the amounts of amyloid and tau deposits in early stage-AD-affected brains of mice and improved their cognitive abilities (Spilman et al., 2010; Majumder et al., 2011). Here, MAPT is linked to Alzheimer disease.